DDInter737 DDInter922
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients suffering from NMOSD. Compared to the anti-CD20 antibody [rituximab], which is also used to treat NMOSD, inebilizumab has broader specificity.[A214280, A214289, A214292, A214295, A214298, A214301] Inebilizumab was granted FDA approval on June 11, 2020, for the treatment of anti-aquaporin 4 positive NMOSD patients. Given its mechanism of action and good safety profile, it may prove useful in the treatment of other conditions linked to autoimmune antibody production or B-cell malignancies.[A214280, A214295] On January 16, 2024, Iinebilizumab also received Health Canada approval for the same indication.
Fingolimod {u} (Compound) treats {v} (Disease) multiple sclerosis
Fingolimod {u} (Compound) binds {v} (Gene) S1PR4
Fingolimod {u} (Compound) is included by {v} (Pharmacologic Class) Sphingosine 1-Phosphate Receptor Modulators
Fingolimod {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Fingolimod {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olanzapine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tizanidine
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Fingolimod (Compound) treats multiple sclerosis (Disease)
Fingolimod (Compound) binds S1PR4 (Gene)
Fingolimod (Compound) is included by Sphingosine 1-Phosphate Receptor Modulators (Pharmacologic Class)
Fingolimod (Compound) causes Cardiac arrest (Side Effect)
Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine
Fingolimod may lead to a major life threatening interaction when taken with Tizanidine
Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib